4/13
07:45 am
ngen
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
Low
Report
NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference
4/7
07:30 am
ngen
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
Medium
Report
NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia
4/2
01:36 pm
ngen
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight [Yahoo! Finance]
Low
Report
The Rise of 6 Emerging Therapies in a Critical Spinal Cord Injury Market Void | DelveInsight [Yahoo! Finance]
3/31
09:23 am
ngen
NervGen Pharma FY GAAP EPS of -$0.61 [Seeking Alpha]
Low
Report
NervGen Pharma FY GAAP EPS of -$0.61 [Seeking Alpha]
3/31
08:03 am
ngen
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
Low
Report
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [Yahoo! Finance]
3/31
08:03 am
ngen
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [TheStreet.com]
Low
Report
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates [TheStreet.com]
3/31
07:45 am
ngen
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
Medium
Report
NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates
3/17
12:24 pm
ngen
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) [Seeking Alpha]
Medium
Report
NervGen Pharma: I See Promise, But The Clock Is Ticking (Rating Downgrade) [Seeking Alpha]
3/12
04:23 pm
ngen
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange [Yahoo! Finance]
Medium
Report
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange [Yahoo! Finance]
3/12
04:15 pm
ngen
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
Medium
Report
NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange
3/4
07:30 am
ngen
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
Medium
Report
NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs
2/18
07:57 am
ngen
NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]
Low
Report
NervGen Pharma to Participate at Upcoming Investor Conferences [Yahoo! Finance]
2/18
07:30 am
ngen
NervGen Pharma to Participate at Upcoming Investor Conferences
Low
Report
NervGen Pharma to Participate at Upcoming Investor Conferences
2/12
04:15 pm
ngen
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
Low
Report
NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams
2/11
07:31 am
ngen
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium [Yahoo! Finance]
Low
Report
NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium [Yahoo! Finance]
2/11
07:28 am
ngen
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium [Canadian Business Journal (Canada)]
Low
Report
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium [Canadian Business Journal (Canada)]
2/11
07:00 am
ngen
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
Low
Report
NervGen Pharma to Present at Unite2Fight Paralysis’ 20th Annual Science and Advocacy Symposium
2/9
08:21 am
ngen
NervGen Pharma appoints new president & CEO [Seeking Alpha]
Low
Report
NervGen Pharma appoints new president & CEO [Seeking Alpha]
2/9
07:00 am
ngen
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
Medium
Report
NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company’s Growth and Execution of Its Mission in Spinal Cord Injury
1/20
07:28 am
ngen
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing [Canadian Business Journal (Canada)]
Low
Report
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing [Canadian Business Journal (Canada)]
1/20
07:00 am
ngen
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing
Medium
Report
NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing